The University of Arizona Wound Care Center Clinical Research Unit

项目总结 大约25%的糖尿病患者经历了糖尿病足溃疡(DFU)。这是一项重要的临床研究 问题是由于没有有效的生物标志物来预测结果，最近没有候选药物 已经得到FDA批准，没有在治疗中广泛有效的疗法。此外，风湿病的流行 糖尿病和无法治愈的DFU在少数民族中最高，例如在美洲原住民和西班牙裔 与社会剥夺和高死亡率有关。 亚利桑那大学(UArizona)是美国西南部领先的公立研究型大学， 研究DFU愈合的理想跨学科研究社区。UArizona和UArizona之间的合作 班纳健康去年为5680名开放性伤口患者提供了服务。从创伤到足科， Banner Health在过去3年中接待了3770名患有糖尿病足溃疡(DFU)的患者。杰弗里·古特纳博士 在通过临床试验研究晚期生物标记物验证方面有既定的历史，而且 通过收集大量高质量的生物样本进行机械性和早期生物标志物识别 和纵向数据(目标1)。这一点得到了亚利桑那州大学庞大的患者群体和Dr。 Gurtner在从人类患者收集的DFU样本中识别Rate细胞亚群的历史。 接下来，我们的目标是通过执行针对DFU的高质量临床试验来创建统一的护理标准， 在历史上很难招募到这些人，也通过收集高质量的数据来解决 具有复杂的病理、共病和社会因素的DFU的异质性。在亚利桑那州大学，古特纳博士 和周博士进行高质量的临床试验，并可以接触到广泛的患者分布和一系列 确保“没有DFU患者未经研究”的技术(目标2)。接下来，我们多样化的患者池将允许 我们需要具体了解社会和环境背景因素(“健康的社会决定因素”； SDH)可能会影响糖尿病的康复和生物标志物，特别是招募多元化和扩张型患者 泳池(目标3)。最后，我们不仅可以访问整个Banner Health Network(BHN)，还可以访问印第安人 为拉美裔社区提供健康网络和外展计划。通过这个庞大的网络 融合了所有人口统计和社会经济地位的人，我们将建立有效的合作 CRU和新的临床站点之间的合作，以产生协作解决问题和高级培训， 共享资源和价值(目标4)。

PROJECT SUMMARY Approximately 25% of diabetic patients experience diabetic foot ulcers (DFUs). This is a significant clinical problem since there are no effective biomarkers for predicting outcomes, no drug candidates that have recently been FDA-approved and no therapies that are widely effective in treatment. Additionally, the prevalence of diabetes and non-healing DFUs are highest among minorities, such as in Native American and Hispanic populations, and associated with social deprivation and high mortality. The University of Arizona (UArizona) is the leading public research university in the American Southwest and an ideal transdisciplinary research community for studying DFU healing. The partnership between UArizona and Banner Health provided service to 5,680 patients with open wounds last year. Ranging from trauma to podiatry, Banner Health saw 3,770 individuals with diabetic foot ulcers (DFUs) in the past 3 years. Dr. Geoffrey Gurtner has an established history in studying both late-stage biomarker validation through clinical trials and also mechanistic and early-stage biomarkers identification through the collection of many high-quality biosamples and longitudinal data (Aim 1). This is supported by both the large patient population at UArizona as well as Dr. Gurtner’s history in identifying rate cell subpopulations in DFU samples collected from human patients. Next, we aim to create a unified Standard of Care through the execution of high-quality clinical trials for DFUs, which historically have been difficult to recruit, and also by collecting high-quality data to address the heterogeneity of DFUs with complex pathologies, co-morbidities, and social factors. At UArizona, Dr. Gurtner and Dr. Zhou conduct high-quality clinical trials and have access to a wide distribution of patients and a range of techniques to make sure that “No DFU Patient Goes Unstudied” (Aim 2). Next, our diverse patient pool will allow us to specifically understand how social and environmental contextual factors (“social determinants of health”; SDH) may affect diabetic healing and biomarkers, specifically be recruiting over a diverse and expansive patient pool (Aim 3). Finally, we have access to not just the entire Banner Health Network (BHN), but also to the Indian Health Network and outreach programs for Latino communities. Through this expansive network that incorporates people of all demographics and socio-economic statuses, we will establish effective collaborations between the CRU and new clinical sites to generate cooperative problem-solving and high-level training, with shared resources and values (Aim 4).